

FIG. 1:




FIG. 2:

	Treatment Groups												Total		
	10 mg IMU-838			30 mg IMU-838			45 mg IMU-838			Placebo					
	N	%		N	%		N	%		N	%		N	%	
Concurrent Use of Corticosteroids	No	28	41.8	26	38.8	26	39.4	26	41.3	106	40.3				
	Yes	25	37.3	30	44.8	29	43.9	26	41.3	110	41.8				
	Total	53	79.1	56	83.6	55	83.3	52	82.5	216	82.1				
		5	7.5	6	9.0	4	6.1	5	7.9	20	7.6				
Biologic-Naïve Patients	Yes	9	13.4	5	7.5	7	10.6	6	9.5	27	10.3				
	Total	14	20.9	11	16.4	11	16.7	11	17.5	47	17.9				
	No	33	49.3	32	47.8	30	45.5	31	49.2	126	47.9				
	Yes	34	50.7	35	52.2	36	54.5	32	50.8	137	52.1				
Total	67	100.0	67	100.0	66	100.0	63	100.0	263	100.0					

FIG. 3:

ITT Data Set	10 mg IMU-838	30 mg IMU-838	45 mg IMU-838	Placebo
Number of Randomized Patients	67	66	66	64
Number of Patients Meeting Primary Endpoint	10	7	9	8
Clinical Remission Rate at Week 10	14.9%	10.6%	13.6%	12.5%

The primary endpoint of clinical remission at week 10 included a composite of patient-reported symptomatic remission (stool frequency Mayo subscore of 0 or 1, rectal bleeding Mayo score of 0) and modified Mayo endoscopy subscore of 0 or 1

Clinical Remission at Week 10
(ITT Data Set)




FIG. 4:




FIG. 5:





FIG. 6:

Endoscopic Healing		10mg		30mg		45mg		Placebo			
Total	missing	6		13		7		7		33	
	no	43	70.5	39	73.6	45	76.3	45	78.9	172	74.8
	yes	18	29.5	14	26.4	14	23.7	12	21.1	58	25.2
	Overall (non-missing)	61	100	53	100	59	100	57	100	230	100
	Total	67		66		66		64		263	

Highlighted is %rate of achieving this endpoint per treatment arm

Clinical Remission		10mg		30mg		45mg		Placebo			
Total	missing	5		10		6		7		28	
	no	52	83.9	49	87.5	51	85	49	86	201	85.5
	yes	10	16.1	7	12.5	9	15	8	14	34	14.5
	Overall (non-missing)	62	100	56	100	60	100	57	100	235	100
	Total	67		66		66		64		263	

Highlighted is %rate of achieving this endpoint per treatment arm

Symptomatic Response = Symptomatic Improvement		10mg		30mg		45mg		Placebo			
Total	missing	5		10		5		6		26	
	no	14	22.6	21	37.5	21	34.4	20	34.5	76	32.1
	yes	48	77.4	35	62.5	40	65.6	38	65.5	161	67.9
	Overall (non-missing)	62	100	56	100	61	100	58	100	237	100
	Total	67		66		66		64		263	

Highlighted is %rate of achieving this endpoint per treatment arm

FIG. 7:

